Retatrutide Shows Remarkable Improvements in Lipid Profile, Cardiovascular Risk, and Liver Fat in Clinical Trials

Recent findings presented at the European Society of Cardiology (ESC) Congress 2024 and shared by VCU Health highlight the significant potential of Eli Lilly’s retatrutide, a novel triple receptor agonist. The drug, targeting GLP-1, GIP, and glucagon receptors, has demonstrated substantial positive effects on cardiovascular risk factors and liver fat reduction in patients with obesity.

• Retatrutide significantly improves lipid profiles, reducing non-HDL-C, apoB, triglycerides, and apoC-III levels.
• The drug effectively reduces liver fat in obese patients, with over 85% achieving levels no longer classified as fatty liver disease.
• Retatrutide shows promise in mitigating long-term harm associated with obesity, including liver, cardiac, metabolic, and renal issues.

Results from a Phase II clinical trial involving 338 patients with obesity or overweight but without diabetes were presented at ESC 2024. Retatrutide demonstrated a dose-dependent improvement in serum lipid profiles over 48 weeks. Key findings include:

• Reduction in non-HDL-C by up to 26.9%.
• Reduction in apoB by up to 24.2%.
• Significant decreases in triglycerides (up to 40.6%) and apoC-III levels (up to 38.0%).
• A reduction in the total number of triglyceride-rich lipoprotein particles (TRLP), with a shift towards smaller average TRLP size.
• A decrease in total and highly atherogenic small LDL particles.
• A notable increase in the average size of HDL particles.
• A dose-dependent decrease in the NMR-derived lipoprotein insulin resistance score, with reductions up to 32.5%.

These improvements suggest that retatrutide could play a crucial role in managing cardiovascular risk factors associated with obesity.

A sub-study led by VCU hepatologist Arun Sanyal focused on retatrutide’s effect on metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease. In this study, a remarkable outcome was observed:

• Over 85% of obese participants with fatty liver disease reduced their liver fat to levels below the diagnostic threshold of 5% by week 48.
• Specifically, 93% of patients taking the higher dose (12mg) achieved this reduction.
• The average weight loss in the liver study was substantial, with patients taking 8mg and 12mg doses experiencing 23.8% and 25.9% weight loss, respectively.

Dr. Sanyal emphasized that retatrutide could serve as a "bottom up" therapy, potentially preventing the progression of liver disease and reversing existing fat accumulation before it causes significant harm. This is particularly significant given the high prevalence of fatty liver disease in obese populations and its strong association with other metabolic and cardiovascular complications.

Retatrutide’s triple receptor agonism targets hunger and satiety pathways, promoting a feeling of fullness and aiding in blood sugar regulation, which contributes to significant weight loss. Experts believe retatrutide could represent the next generation of obesity treatments, potentially succeeding current therapies like tirzepatide. The drug is currently in Phase III clinical trials for obesity, type 2 diabetes, and other conditions. Given these promising results, there is potential for retatrutide to be approved not only for weight management but also for addressing associated cardiovascular and liver health issues.

• ESC 2024: Retatrutide improves lipid and cardiovascular risk profile in Phase II trial, Clinical Trials Arena.
• Retatrutide wiped out fat in liver of obese patients, VCU Health.